Breast cancer suppression by aplysin is associated with inhibition of PI3K/AKT/FOXO3a pathway.

摘要: // Xinling Zhang 1 , Tingting Zhuang 2 Zhengyan Liang Li Meilan Xue Jia Liu and Hui The Institute of Human Nutrition, Medical College Qingdao University, 266021, China Key Laboratory Marine Drugs, Chinese Ministry Education, Glycoscience & Glycotechnology Shandong Province, School Medicine Pharmacy, Ocean University China, 266003, Correspondance to: Liang, email: ajgqdfy@163.com Zhang, ruoxi_67@163.com Keywords: aplysin, PI3K/AKT, cell proliferation, apoptosis, breast cancer Received: December 15, 2016      Accepted: June 04, 2017      Published: July 12, 2017 ABSTRACT Aplysin, a bromosesquiterpene isolated from Aplysia kurodai, was explored as potential anti-breast agent by us. However, the mechanisms underlying anticarcinogenic effect aplysin remain unclear. Here, found to remarkably suppress tumor growth in vivo inhibit proliferation promote apoptosis vitro . Additionally, we demonstrated that attained these effects part down-regulating PI3K/AKT/FOXO3a signaling pathway. Aplysin treatment inhibited phosphorylation levels AKT (Ser-473) AKT-dependent FOXO3a (Ser-253) lines tissues. expression FOXO3a-targeted genes were also destabilized cyclin D1 Bcl-XL declined; however, p21 CIP1 p27 KIP1 Bim, TRAIL FasL increased both Furthermore, activation PI3K/AKT pathway an activator silencing shRNA protected cells mediated suppression apoptosis. In summary, our findings revealed could progression inhibiting pathway, thereby suggesting role chemoprevention drug for patients with cancer.